Journal of Surgical Research
Volume 158, Issue 1 , Pages 15-19 , January 2010

MG-132 Inhibits Carcinoid Growth and Alters the Neuroendocrine Phenotype

  • Jui-yu Chen, M.D.

      Affiliations

    • Endocrine Surgery Research Laboratories, Department of Surgery, University of Wisconsin, Madison, Wisconsin
    • Department of Surgery, Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan
    • ,
  • Mackenzie R. Cook, B.A.

      Affiliations

    • Endocrine Surgery Research Laboratories, Department of Surgery, University of Wisconsin, Madison, Wisconsin
    • ,
  • Scott N. Pinchot, M.D.

      Affiliations

    • Endocrine Surgery Research Laboratories, Department of Surgery, University of Wisconsin, Madison, Wisconsin
    • ,
  • Muthusamy Kunnimalaiyaan, Ph.D.

      Affiliations

    • Endocrine Surgery Research Laboratories, Department of Surgery, University of Wisconsin, Madison, Wisconsin
    • ,
  • Herbert Chen, M.D., F.A.C.S.

      Affiliations

    • Endocrine Surgery Research Laboratories, Department of Surgery, University of Wisconsin, Madison, Wisconsin
    • Corresponding Author InformationTo whom correspondence and reprint requests should be addressed at Department of Surgery, University of Wisconsin, H4/722 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792.

Received 13 January 2009

References 

  1. Pinchot SN, Holen K, Sippel RS, et al. Carcinoid tumors. Oncologist. 2008;13:1255
  2. Chen H, Hardacre J, Uzar A, et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?. J Am Coll Surg. 1998;187:88;discussion 92
  3. Lal A, Chen H. Treatment of advanced carcinoid tumors. Curr Opin Oncol. 2006;18:9
  4. Shah S, Potter M, Callery M. Ubiquitin proteasome pathway: Implications and advances in cancer therapy. Surg Oncol. 2001;10:43
  5. Adams J. Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol. 2002;14:628
  6. Adams J. The proteasome: A suitable antineoplastic target. Nat Rev Cancer. 2004;4:349
  7. Richardson PG, Mitsiades C, Hideshima T, et al. Bortezomib: Proteasome inhibition as an effective anticancer therapy. Annu Rev Med. 2006;57:33
  8. Wu WK, Sung JJ, Wu YC, et al. Bone morphogenetic protein signalling is required for the anti-mitogenic effect of the proteasome inhibitor MG-132 on colon cancer cells. Br J Pharmacol. 2008;154:632
  9. Yan XB, Yang DS, Gao X, et al. Caspase-8 dependent osteosarcoma cell apoptosis induced by proteasome inhibitor MG132. Cell Biol Int. 2007;31:1136
  10. Codony-Servat J, Tapia MA, Bosch M, et al. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther. 2006;5:665
  11. Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA, et al. Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol Cancer Ther. 2007;6:1151
  12. Hardt SE, Sadoshima J. Glycogen synthase kinase-3beta: A novel regulator of cardiac hypertrophy and development. Circ Res. 2002;90:1055
  13. Wang Q, Wang X, Hernandez A, et al. Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells. J Biol Chem. 2002;277:36602
  14. Kunnimalaiyaan M, Ndiaye M, Chen H. Neuroendocrine tumor cell growth inhibition by ZM336372 through alterations in multiple signaling pathways. Surgery. 2007;142:959;discussion 959
  15. Van Gompel JJ, Kunnimalaiyaan M, Holen K, et al. ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells. Mol Cancer Ther. 2005;4:910
  16. Sippel RS, Carpenter JE, Kunnimalaiyaan M, et al. Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol. 2003;285:G245
  17. Kunnimalaiyaan M, Traeger K, Chen H. Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol. 2005;289:G636
  18. Wang ZB, Liu YQ, Cui YF. Pathways to caspase activation. Cell Biol Int 2205;29:489.
  19. Liao X, Thrasher JB, Holzbeierlein J, et al. Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer. Endocrinology. 2004;145:2941
  20. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, et al. Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res. 2005;65:2076
  21. Shakoori A, Ougolkov A, Yu ZW, et al. Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun. 2005;334:1365
  22. Kappes A, Vaccaro A, Kunnimalaiyaan M, et al. ZM336372, a Raf-1 activator, inhibits growth of pheochromocytoma cells. J Surg Res. 2006;133:42
  23. Kappes A, Vaccaro A, Kunnimalaiyaan M, et al. Lithium ions: A novel treatment for pheochromocytomas and paragangliomas. Surgery. 2007;141:161;discussion 165
  24. Drexler HC. The role of p27Kip1 in proteasome inhibitor induced apoptosis. Cell Cycle. 2003;2:438
  25. Almond JB, Cohen GM. The proteasome: a novel target for cancer chemotherapy. Leukemia. 2002;16:433
  26. Holecek M, Muthny T, Kovarik M, et al. Proteasome inhibitor MG-132 enhances whole-body protein turnover in rat. Biochem Biophys Res Commun. 2006;345:38
  27. Inoue S, Nakase H, Matsuura M, et al. The effect of proteasome inhibitor MG132 on experimental inflammatory bowel disease. Clin Exp Immunol. 2009;156:172

PII: S0022-4804(09)00288-1

doi: 10.1016/j.jss.2009.05.032

Journal of Surgical Research
Volume 158, Issue 1 , Pages 15-19 , January 2010

Article Tools

* Image Usage & Resolution